EVC2 and lung cancer: Hence, the three candidate biomarkers illustrated in Figure 6B (APOA4 273–283, FIBA 5–16, and LBN 306–313) were individually considered as clinically useful biomarkers for both early detection and tumor staging of lung cancer, however, integrative measurement of biomarkers such as Figure 4B would provide more accurate diagnosis, that could be achievable by MRM-based diagnostic approaches in the future.